EMA starts review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine

EMA has started a review of medicines containing fluorouracil (also known as 5-fluorouracil or 5-FU) and the related medicines capecitabine, tegafur and flucytosine, which are converted to fluorouracil in the body. The review will examine existing screening methods and their value in identifying patients at increased risk of severe side effects.

TESCO TO ESTABLISH ITS CENTRAL EUROPEAN BUSINESS SERVICES CENTRE IN HUNGARY

Tesco has chosen Budapest to host its new business services centre (BSC) supporting its operations in the Central European region. The new Center of Excellence unit of the British retail trade company that will fulfill IT technology, financial and HR-related functions is planned to start its operation in April, creating some 800 high value added […]

First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban

EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ondexxya (andexanet alfa). This medicine is to be used as an antidote for adult patients taking the anticoagulant (clot-preventing) medicines  apixaban or rivaroxaban , when reversal of their action is needed  due to life-threatening or uncontrolled bleeding .